Here, we report the successful generation of such an IgG fusion protein (CD19-TRAIL) and show that CD19-TRAIL efficiently kills CD19-positive (CD19+) BCP-ALL cell lines in vitro and in vivo and is also effective in BCP-ALL xenograft mouse models. Here, CD19 is linked to acute lymphoblastic leukemia.